ALBO - Albireo Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Albireo Pharma, Inc.

10 Post Office Square
Suite 502 South
Boston, MA 02109
United States
857-254-5555
http://www.albireopharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees55

Key Executives

NameTitlePayExercisedYear Born
Mr. Ronald H. W. CooperCEO, Pres & Director899.19kN/A1963
Dr. Jan P. MattssonChief Scientific Officer & MD (Sweden) and Co-Founder525.27kN/A1964
Ms. Martha J. CarterChief Regulatory Officer584.22kN/A1952
Dr. Per-Goran GillbergCo-Founder & VP of Devel.N/AN/AN/A
Mr. Simon N.R. HarfordCFO & TreasurerN/AN/A1961
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Corporate Governance

Albireo Pharma, Inc.’s ISS Governance QualityScore as of December 3, 2019 is 8. The pillar scores are Audit: 10; Board: 4; Shareholder Rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.